A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

February 29, 2012

Conditions
Asthma
Interventions
DRUG

Formoterol/Budesonide

formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

DRUG

Foraseq

foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

DRUG

Alenia

Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.

Trial Locations (5)

Unknown

Centro de Referencia em Enfermidades Respiratoria e Alergica, Salvador

Hospital de Clinicas UFPR, Curitiba

IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada, São Paulo

Stelmach Pesquisa Clinica, São Paulo

Clinica de Alergia Martti Antila, Sorocaba

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY